MARKET

GRTX

GRTX

Galera Therapeutics, Inc.
NASDAQ
1.740
+0.010
+0.58%
After Hours: 1.650 -0.09 -5.17% 17:56 09/30 EDT
OPEN
1.760
PREV CLOSE
1.730
HIGH
1.860
LOW
1.710
VOLUME
78.34K
TURNOVER
0
52 WEEK HIGH
8.50
52 WEEK LOW
1.120
MARKET CAP
46.67M
P/E (TTM)
-0.6652
1D
5D
1M
3M
1Y
5Y
Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket
Gainers
Benzinga · 6d ago
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfo...
GlobeNewswire · 6d ago
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Benzinga · 09/07 09:16
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 09/06 17:43
AVYA, NEON and RGTI among mid-day movers
Gainers: IVERIC bio (ISEE) +57%. ChannelAdvisor Corporation...
Seekingalpha · 09/06 16:58
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 09/02 12:07
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfo...
GlobeNewswire · 09/01 11:00
Recap: Galera Therapeutics Q2 Earnings
  Galera Therapeutics (NASDAQ:GRTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 08/09 13:38
More
About GRTX
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. It has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Webull offers kinds of Galera Therapeutics Inc stock information, including NASDAQ:GRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRTX stock methods without spending real money on the virtual paper trading platform.